ArticleFrontiers in immunology2013
The schistosoma granuloma: friend or foe?
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 229 citations in OpenAlex.
- Manipulation of host response and trajectory of parasite survival: A damage-response framework perspective.Virulence · 2026Review
- StandardizedPathogens (Basel, Switzerland) · 2026Article
- Stage-specific remodeling of the pulmonary microenvironment during Paragonimus proliferus infection in a rat model.PLoS neglected tropical diseases · 2026Article
- Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment.PLoS neglected tropical diseases · 2026Article
- No Simple Fluke: Schistosomiasis as an Emerging Regulator of Haematopoiesis.Parasite immunology · 2026Review
- In vivo assessment of anti-helminthic and anti-inflammatory effects of Fucoidan on Schistosoma mansoni immature stages.Scientific reports · 2026Article
- Schistosoma mansoni Infections Are Associated With Fecal Calprotectin Markers of Gut Inflammation After Accounting for HIV, Hepatitis B, and Malaria.The Journal of infectious diseases · 2026Article
- Praziquantel efficacy and post-treatment reinfection and incidence of Schistosoma mansoni among school-aged children in Northern Uganda: a 24-week cohort study in a high transmission focus.BMC infectious diseases · 2026Article
- Clinical outcomes associated with schistosome infection and alcohol use: A systematic scoping review.PLoS neglected tropical diseases · 2026Article
- Parasites as Modulators of Angiogenesis: Implications for Vascular Biology and Pathogenesis.Pathogens (Basel, Switzerland) · 2026Review
- Surface Charge-Dependent Targeting and Penetration of Magnetic Nanoparticles into Eggs and Adult Worms ofPharmaceutics · 2026Article
- Schistosomiasis in Yemen: Focal Persistence, Possible Resurgence, and Challenges to Elimination.Research and reports in tropical medicine · 2026Review
- Sex in Immune Cells and Parasitic Diseases - A Complex Relationship.Immunological reviews · 2026Review
- Schistosoma haematobium infection is associated with oncogenic gene expression in Cervical Mucosa, with enhanced effects following treatment: A pilot study.PLoS neglected tropical diseases · 2025Article
- Thrombocytopenia in murine schistosomiasis is associated with platelet uptake by liver macrophages that have a distinct activation phenotype.PLoS pathogens · 2025Article
- An exploratory study to assess the influence of schistosomiasis on the occurrence of dengue virus in Madagascar.Infectious diseases of poverty · 2025Article
- High Schistosoma mansoni infection intensity is associated with distinct gut microbiota and low levels of systemic cytokines in children along the Albert-Nile, Northern Uganda.BMC microbiology · 2025Article
- A major ecological niche of eosinophils in evolvingScience advances · 2025Article
- SOX9 plays an essential role in myofibroblast driven hepatic granuloma integrity and parenchymal repair during schistosomiasis-induced liver damage.PLoS pathogens · 2025Article
- Merck Open Global Health Library in vitro screening against Schistosoma mansoni identified two new substances with antischistosomal activities for further development.Parasites & vectors · 2025Article
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infection of man with Schistosoma species of trematode parasite causes marked chronic morbidity. Individuals that become infected with Schistosomes may develop a spectrum of pathology ranging from mild cercarial dermatitis to severe tissue inflammation, in particular within the liver and intestines, which can lead to life threatening hepatosplenomegaly. It is well established that the etiopathology during schistosomiasis is primarily due to an excessive or unregulated inflammatory response to the parasite, in particular to eggs that become trapped in various tissue. The eggs forms the foci of a classical type 2 granulomatous inflammation, characterized by an eosinophil-rich, CD4(+) T helper (Th) 2 cell dominated infiltrate with additional infiltration of alternatively activated macrophages (M2). Indeed the sequela of the type 2 perioval granuloma is marked fibroblast infiltration and development of fibrosis. Paradoxically, while the granuloma is the cause of pathology it also can afford some protection, whereby the granuloma minimizes collateral tissue damage in the liver and intestines. Furthermore, the parasite is exquisitely reliant on the host to mount a granulomatous reaction to the eggs as this inflammatory response facilitates the successful excretion of the eggs from the host. In this focused review we will address the conundrum of the S. mansoni granuloma acting as both friend and foe in inflammation during infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.